BBTX — Bambusa Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 2044950 ·
Last close
$16.35
Market Cap
$832.91M
52W High
$17.65
52W Low
$13.60
ADV30
400,627
Next earnings
—
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 77,496,000 46,534,000 148,454,000
Dec 2025 — — — — 95,713,000 50,643,000 144,883,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-77,188,000
Inventory
—
Receivables
$1,226,000
ST Investments
$24,941,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -40,696,000 -41,087,000 95,713,000 144,883,000 -49,170,000 -39,804,000
Dec 2024 0 -13,880,000 -13,741,000 9,764,000 23,312,000 -13,548,000 -4,634,000

Peers — same industry

TickerNameMarket CapLastDaily %
MGTX MeiraGTx Holdings plc $826.80M $8.46 —
PRME Prime Medicine, Inc. $854.20M $3.84 —
GLUE Monte Rosa Therapeutics, Inc. $775.03M $9.07 —
ODTX Odyssey Therapeutics, Inc. $931.07M $19.37 —
AURA Aura Biosciences, Inc. $744.13M $7.15 —

News headlines (Yahoo Finance, 1h cache)

Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
2026-10-30 00:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.